11 completed, 6 recruiting, 3 terminated, 3 unknown. 6 Phase 3, 5 Not applicable, 2 Phase 1, 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 3, Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 5 | Completed 4, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow ADPKD: new trials by email Literature Review of ADPKD trials Research Report on ADPKD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Somatosensory Phenotyping of ADPKD Quantitative Sensory Testing, Questionnaires regarding pain and quality of life - ADPKD, Pain | Recruiting | Universitaire Ziekenhuizen KU Leuven | 150 | 2025-09-09 | 2025-11-17 | |
| HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life Hydrochlorothiazide 25 mg, Placebo - ADPKD | Phase 3 | Recruiting | University Medical Center Groningen | 300 | 2024-07-31 | 2026-08-25 |
| Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? Ketone ester - ADPKD | Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 20 | 2023-11-01 | 2023-10-25 |
| Genetic Testing in Autosomal Dominant Polycystic Kidney Disease Survey - ADPKD | Completed | University of California, San Francisco | 226 | 2023-06-01 | 2024-12-16 | |
| A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease RGLS8429, Placebo - Autosomal Dominant Polycystic Kidney Disease, ADPKD | Phase 1 | Completed | Regulus Therapeutics Inc. | 68 | 2022-10-06 | 2025-06-03 |
| Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Lixivaptan, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Terminated | Palladio Biosciences | 12 | 2021-10-28 | 2023-02-06 |
| Kidney Sodium Functional Imaging Sodium-23 MRI - Chronic Kidney Disease, Nephrolithiasis | Recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 200 | 2021-09-16 | 2025-02-12 | |
| Analysis of Patients With Autosomal Dominant Polycystic Kidney Autosomal Dominant Polycystic Kidney, ADPKD | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 180 | 2021-02-20 | 2025-01-06 | |
| Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Ketogenic diet, 3-days water-fasting, Control - ADPKD | Not applicable | Completed | University of Cologne | 63 | 2021-01-10 | 2022-08-24 |
| Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt Sodiumchloride, Protein, Placebo comparator (salt) - Polycystic Kidney, Autosomal Dominant, ADPKD | Not applicable | Unknown | Esther Meijer | 12 | 2020-09-07 | 2020-11-05 |
| Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Lixivaptan - Polycystic Kidney Disease, Adult, ADPKD | Phase 3 | Terminated | Palladio Biosciences | 7 | 2020-09-02 | 2023-04-10 |
| Short Term Induction of Ketosis in PKD Fasting, Ketogenic diet - ADPKD | Not applicable | Completed | University of Cologne | 10 | 2020-07-01 | 2021-09-14 |
| Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study ADPKD | Recruiting | Children's Hospital of Philadelphia | 300 | 2019-10-10 | 2026-06-15 | |
| A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Bardoxolone methyl oral capsule, Placebo oral capsule - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Terminated | Biogen | 667 | 2019-05-29 | 2025-06-03 |
| Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease Metformin, Tolvaptan - ADPKD | Phase 3 | Unknown | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 150 | 2019-01-30 | 2018-12-07 |
| ADPKD Alterations in Hepatic Transporter Function ADPKD, Autosomal Dominant Polycystic Kidney Disease | Completed | University of North Carolina, Chapel Hill | 24 | 2018-09-17 | 2020-03-25 | |
| Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Tesevatinib, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 2 | Completed | Kadmon, a Sanofi Company | 80 | 2017-10-12 | 2023-02-06 |
| Statin Therapy in Patients With Early Stage ADPKD Pravastatin, Placebo - ADPKD, Autosomal Dominant Polycystic Kidney | Phase 4 | Active not recruiting | University of Colorado, Denver | 150 | 2017-08-31 | 2025-05-08 |
| Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease water - ADPKD | Not applicable | Completed | Copenhagen University Hospital, Rigshospitalet | 40 | 2015-09-01 | 2017-10-02 |
| Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping ADPKD | Completed | The Rogosin Institute | 79 | 2013-12-01 | 2022-03-02 |
Showing 20 of 24. Sign in to see all of them.
Polycystic Kidney, Autosomal Dominant (24) · Fasting (2) · Ketosis (2) · Kidney Diseases (2) · Renal Insufficiency, Chronic (2) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Glomerulonephritis (1) · Hematologic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hypertension (1) · Nephrolithiasis (1) · Pain (1) · Polycystic Kidney Diseases (1) · Polycystic liver disease (1) · Polyuria (1)
Abnormalities, Multiple (24) · Ciliopathies (24) · Congenital Abnormalities (24) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (24) · Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Genetic Diseases, Inborn (24) · Kidney Diseases, Cystic (24) · Male Urogenital Diseases (24) · Urogenital Diseases (24) · Urologic Diseases (24) · Polycystic Kidney Diseases (23) · Kidney Diseases (22) · Pathological Conditions, Signs and Symptoms (4) · Metabolic Diseases (3)
Diet, Ketogenic (2) · lixivaptan (2) · Angptl4 protein, mouse (1) · Hydrochlorothiazide (1) · Metformin (1) · Pharmaceutical Preparations (1) · Polymorphism, Genetic (1) · Pravastatin (1) · Proteins (1) · Quality of Life (1) · Salts (1) · Sirolimus (1) · Spironolactone (1) · Sugars (1) · Surveys and Questionnaires (1)
Palladio Biosciences (2) · University of Cologne (2) · University of Colorado, Denver (2) · Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari (1) · Biogen (1) · Children's Hospital of Philadelphia (1) · Copenhagen University Hospital, Rigshospitalet (1) · Esther Meijer (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Kadmon, a Sanofi Company (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Medical University of Vienna (1) · Ospedale San Raffaele (1) · Regional Hospital Holstebro (1) · Regulus Therapeutics Inc. (1)
United States (11) · Germany (4) · Italy (4) · Belgium (3) · Spain (3) · Australia (2) · Austria (2) · France (2) · Netherlands (2) · United Kingdom (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · Hungary (1)
Arlene Chapman, MD (1) · Erling B Pedersen, Professor (1) · Esther Meijer, Dr. (1) · Gaetano La Manna, MD (1) · Gere Sunder-Plassmann, MD (1) · Jan de Hoon, MD, PhD, MSc (1) · Jesper N Bech, MD, Ph.d. (1) · Jon Blumenfeld, MD (1) · Kim Brouwer, PharmD, PhD (1) · Lisa Guay-Woodford, MD (1) · Loreto Gesualdo (1) · Meyeon Park, MD (1) · Michel B Chonchol, MD (1) · Michel Chonchol, MD (1)
PMID 39356039, PMID 41385299, PMID 30803706, PMID 37935200, PMID 38151173, PMID 38688870, PMID 38837240, PMID 39331470, PMID 41077128, PMID 41643210, PMID 41701531
R01DK097081 (1), R35GM122576 (1)